

To:

Jia-Ping Yan

Science Editor, Editorial Office of **WJG**

April 15, 2019

Dear Dr. Yan,

Thank you for your response and for the reviewers' further comments concerning our manuscript entitled "**LncRNA HOXA11-AS promotes cell proliferation and invasion via SRSF1 and functions as a biomarker in gastric cancer**" (ID: 47868). We have addressed the comments meticulously, and the amendments are made in the revised manuscript. And point by point response to the reviewers' comments is listed below. We hope that the revised version of this document is now acceptable for publication in your journal.

Reviewer #1: This article brings novel and useful information regarding the mechanism of action of LncRNA HOXA11-AS in gastric cancer, demonstrated to have the potential to promote proliferation and invasion in this type of tumor, possibly via SRSF1. Serum LncRNA HOXA11-AS correlated also with tumor size, TNM stage and lymph node metastases. Moreover, down-regulation of LncRNA HOXA11-AS has proven to be associated with a better survival in gastric cancer. The authors emphasize the role of LncRNA HOXA11-AS as diagnostic and prognostic biomarker in stomach cancer, therefore this data present an important clinical usefulness.

Response: Thank you for your comments. We will redouble our efforts to apply the molecular detection of LncRNA HOXA11-AS to clinical practice as soon as possible.

Reviewer #2: This manuscript describes about lncRNA HOXA11-AS promoting cell proliferation and invasion via SRSF1. Low serum HOXA11-AS expression contributes into the better overall survival in gastric cancer patients. The calculation for p value may be indicated in figure 3.

Response: Thank you for your comments.

Thank you again for your patient editing of our paper. We are pleased to see the paper is in a better shape now.

I look forward to hearing from you soon.

Yours sincerely,

Baozhen Liu

E-mail: zhebaonnt3411@163.com